Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 214

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Blood blood.2024025897.

https://doi.org/10.1182/blood.2024025897

Published: 2024

Includes: Supplemental data

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Sabine Ringkowski, Adam Bryant, Slavisa Ninkovic, Nada Hamad, Georgia McCaughan, Shaji Kumar, Andrew Spencer, Hang Quach

Blood (2024) 144 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2024-207609

Published: 2024

Journal Articles

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

Betty Gration, Cameron Wellard, Elizabeth Moore, Marianne Tan, Matthew Murphy, Kenneth J C Lim, James Rowland, Nada Hamad, Rajeev Rajagopal, Peter Mollee, Andrew Spencer, Hang Quach, Georgia McCaughan

Blood (2024) 144 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2024-201790

Published: 2024

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar

Blood (2024) 144 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2024-199773

Published: 2024

Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Blood (2024) 144 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2024-199542

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Betty Gration, Cameron Wellard, Elizabeth Moore, Peter Mollee, Ian H. Kerridge, Andrew Spencer, Anita Shetty, Bart Baker, Cecily Forsyth, Jessica Heenan, Zoe K McQuilten, Erica M. Wood, Georgia McCaughan

Blood (2024) 144 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2024-199451

Published: 2024

Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2024-209952

Published: 2024

Journal Articles

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Hyesuk Lee, Peter Mollee, Anita C Shetty, Helen Weston, Nina Byard, Khoa Le, Zoe K McQuilten, Hang Quach, Andrew Spencer

Blood (2024) 144 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2024-209640

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2023-186241

Published: 2023

Journal Articles

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Slavisa Ninkovic, Wee-Joo Chng, Andrew Spencer, Peter Mollee, Jay Hocking, Phoebe Joy Ho, Wojt Janowski, Kihyun Kim, Karen Dun, Zoe K McQuilten, Fiona Chen, Hang Quach

Blood (2023) 142 (Supplement 1): 3325.

https://doi.org/10.1182/blood-2023-173896

Published: 2023

Journal Articles

GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial

Sebastian Grosicki, Torben Plesner, Wojciech Jurczak, Jakub Radocha, Ehsan Malek, Ida Hiemstra, Lauren K. Brady, Jenny Chen, Nian Gong, Charlotte Hindsberger, Andrew Spencer

Blood (2023) 142 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2023-179504

Published: 2023

Journal Articles

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

Fredrik Schjesvold, Andrew Spencer, Yael C. Cohen, Enrique M Ocio, Jordi López-Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, Noriko Doki, Rebecca Kan, Karolina Kulec, Gina Trabucco, Stan Ye, Romain Sechaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab

Blood (2023) 142 (Supplement 1): 4752.

https://doi.org/10.1182/blood-2023-177908

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter M. Voorhees, Irwindeep Sandhu, Matthew W. Jenner, Dean Smith, Michele Cavo, Niels WCJ van de Donk, Meral Beksac, Philippe Moreau, Hartmut Goldschmidt, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, Craig C. Hofmeister

Blood (2023) 142 (Supplement 1): 210.

https://doi.org/10.1182/blood-2023-181765

Published: 2023

NARROW

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only